SCHEMBL21758873

SCHEMBL21758873

CC([C@H](O)c1ccccc1)N1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.54
KCNH2 Q12809 6/20 0.54
GRIN2B Q13224 6/20 0.54
GRIN1 Q05586 4/20 0.54
GRIN2D O15399 3/20 0.54
GRIN2A Q12879 3/20 0.54
GRIN2C Q14957 3/20 0.54
GRIN3B O60391 2/20 0.54
GRIN3A Q8TCU5 2/20 0.54
CYP1A2 P05177 5/20 0.53
CYP3A4 P08684 5/20 0.53
CYP2C9 P11712 4/20 0.53
KCNA5 P22460 4/20 0.53
CYP2C19 P33261 4/20 0.53
KCNE1 P15382 1/20 0.52
ADRA2A P08913 5/20 0.51
HTR2A P28223 5/20 0.51
ADRA1A P35348 5/20 0.51
HTR2B P41595 4/20 0.51
SIGMAR1 Q99720 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2699322 1.00 CYP2D6 (0.54) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL21093474 1.00 CYP2D6 (0.54) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL2714074 1.00 CYP2D6 (0.54) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL597166 1.00 CYP2D6 (0.54) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL2714385 1.00 CYP2D6 (0.54) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL2712368 1.00 CYP2D6 (0.54) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL523547 1.00 CYP2D6 (0.54) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL21093519 0.98 CYP2D6 (0.55) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
Hydrochloric Acid SCHEMBL8002216 0.98 CYP2D6 (0.52) CYP2D6KCNH2GRIN2BGRIN1GRIN2D
SCHEMBL2712934 0.98 CYP2D6 (0.55) CYP2D6KCNH2GRIN2BGRIN1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689353-B2 Method for the manufacture of Efavirenz NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) 2020-06-23 US disclosed
US-20200062722-A1 Method For The Manufacture of Efavirenz NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689353-B2 Method for the manufacture of Efavirenz CYP2F1, CYP2D6, CYP3A4 CYP2D6 2/4885KCNH2 1894/4885GRIN2B 3250/4885
US-20200062722-A1 Method For The Manufacture of Efavirenz CYP2F1, CYP2D6, CYP3A4 CYP2D6 2/4885KCNH2 1894/4885GRIN2B 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.